Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000816596 | SCV000957113 | pathogenic | Congenital hyperammonemia, type I | 2022-11-25 | criteria provided, single submitter | clinical testing | Experimental studies have shown that this missense change affects CPS1 function (PMID: 24813853). This variant disrupts the p.Arg850 amino acid residue in CPS1. Other variant(s) that disrupt this residue have been observed in individuals with CPS1-related conditions (PMID: 17310273), which suggests that this may be a clinically significant amino acid residue. For these reasons, this variant has been classified as Pathogenic. This sequence change replaces arginine, which is basic and polar, with histidine, which is basic and polar, at codon 850 of the CPS1 protein (p.Arg850His). This variant is present in population databases (rs767694281, gnomAD 0.003%). This missense change has been observed in individual(s) with carbamoylphosphate synthetase 1 deficiency (PMID: 15617192, 22575620, 27150549). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 659565). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt CPS1 protein function. |
Baylor Genetics | RCV003467478 | SCV004214496 | pathogenic | Pulmonary hypertension, neonatal, susceptibility to | 2024-01-30 | criteria provided, single submitter | clinical testing |